BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elessa D, Talbot A, Lombion N, Harel S, Galicier L, Veyradier A, Joly B, Andreoli A, Rigaudeau S, Azoulay É, Coppo P, Royer B, Arnulf B. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. Br J Haematol 2019;188:338-40. [DOI: 10.1111/bjh.16333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Buetler VA, Agbariah N, Schild DP, Liechti FD, Wieland A, Andina N, Hammann F, Kremer Hovinga JA. Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature. Front Med (Lausanne) 2022;9:890661. [PMID: 35655852 DOI: 10.3389/fmed.2022.890661] [Reference Citation Analysis]
2 Terao T, Tsushima T, Miura D, Ikeda D, Fukumoto A, Kuzume A, Tabata R, Narita K, Takeuchi M, Matsue K. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review. Leuk Lymphoma 2022;63:1102-10. [PMID: 35373680 DOI: 10.1080/10428194.2022.2057485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Colonne CK, Favaloro EJ, Pasalic L. The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer. Healthcare 2022;10:557. [DOI: 10.3390/healthcare10030557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood 2021;137:1310-7. [PMID: 33512445 DOI: 10.1182/blood.2019003810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]